Australia's CSL rises after Jefferies sees plasma yield upside
CSL•CSL shares rose as much as 1.62% to A$184.40 after Jefferies said its US plasma platform shift could improve collection yield by up to 15%. Jefferies maintained its hold rating and said benefits may emerge gradually, with collection disruption a key risk.
1. Platform transition
CSL plans to replace Terumo systems with Haemonetics equipment across about 330 US centres by the end of 2027. Jefferies said channel checks suggest the new platform could improve plasma collection yield by up to 15%.
2. Risks and goals
Jefferies said a single newer platform aligns with CSL's cost-per-litre and gross margin goals, though benefits are likely to emerge gradually. It identified collection disruption during the changeover as a key risk and is watching for disclosures on costs, savings and impairment.
